Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003095 · ClinicalTrials.gov registry record
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
A clinical trial, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 26
- Enrollment target
NCT00003095 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 26 participants.
The verdict
NCT00003095 has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy for breast cancer may damage the genes of cells. This may lead to the development of secondary cancers. PURPOSE: Pilot study to evaluate the degree of gene damage following chemotherapy in women with stage II or stage III breast cancer involving four to nine axillary lymph nodes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 1997-11 |
| Est. Completion | 2001-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003095
The ClinicalTrials.gov registry entry for NCT00003095 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00003095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003095 about?
NCT00003095 is a clinical study titled "S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy for breast cancer may damage the genes of cells. This may lead to the development of secondary cancers. PURPOSE: Pilot study to evaluate the degree of gene damage following chemotherapy in women with stage II or stage III breast cancer involving four to nine ax...
What is the current status of trial NCT00003095?
This trial is currently completed. The enrollment target is 26 participants. The study started on 1997-11. Estimated completion is 2001-02.
Who is sponsoring clinical trial NCT00003095?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.